INTRODUCTION {#s1}
============

Based on the latest GLOBOCAN estimates, there were approximately 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide in 2012 \[[@R1]\]. Developing countries accounted for almost 57% of new cancer cases and 65% of cancer-related deaths \[[@R1]\]. According to the trend in cancer incidence, the expected number of new cancer cases will reach 22.2 million worldwide in 2030 \[[@R2]\]. Leading risk factors for cancer development include tobacco use, overweight/obesity, physical inactivity, and infection \[[@R1]\]. Moreover, molecular epidemiological studies have demonstrated that genetic factors including single nucleotide polymorphisms (SNPs), may also play an important role in carcinogenesis \[[@R3]--[@R9]\].

As the gatekeeper for cellular growth and division, the tumor suppressor protein p53 maintains genomic stability and regulating cell growth, division, and apoptosis. Dysfunctional p53 protein can lead to the initiation and progression of tumors \[[@R10]\]. Mouse double minute 4 (MDM4) protein is a structural homolog of MDM2, which contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus. MDM4 has been shown to inhibit p53 transcriptional activity directly by binding to its transcriptional activation domain. Overactive MDM4 reduces p53 tumor suppression function and contributes to tumor formation and progression \[[@R11]\]. The MDM4 protein can also inhibit the degradation of MDM2 by interacting with its RING finger domain \[[@R11]\]. Overexpression of MDM4 is associated with tumor progression and poor prognosis \[[@R12]--[@R14]\]. Previous molecular epidemiology studies suggest that genetic variations in *MDM4* gene are associated with risk of various types of cancer \[[@R15]--[@R20]\].

Among the many *MDM4* polymorphisms, a common genetic variant rs4245739 A \> C has been widely investigated for its association with cancer susceptibility \[[@R21]--[@R28]\]. This polymorphism is located in the 3′ untranslated region (UTR) of the *MDM4* gene, and creates a miR-191 target site that can lead to decreased expression of MDM4. However, the studies have generated controversial results regarding the association between this polymorphism and cancer risk. The possible reasons for the inconsistencies include differences in ethnicity and geographic location, as well as the limited sample size. To date, no meta-analysis has been conducted to comprehensively investigate the association of *MDM4* rs4245739 A \> C with overall cancer risk. To address the controversy regarding this association, we performed the current meta-analysis to precisely define the effect of *MDM4* rs4245739 A \> C polymorphism on overall cancer risk.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

A total of 81 articles were retrieved after an initial literature search in MEDLINE, EMBASE, and Chinese Biomedical (CBM) databases (Figure [1](#F1){ref-type="fig"}). After full text review, 73 articles were excluded for the following reasons: review articles, duplicate studies, non-case-control study design, genotype distributions were not available, or no evaluation of the association between *MDM4* rs4245739 A \> C polymorphism and cancer risk. Ultimately, we found that only eight articles \[[@R21]--[@R28]\] met the inclusion criteria (Table [1](#T1){ref-type="table"}). Among the eight articles, several investigations involving subjects from different areas were divided by area \[[@R22], [@R23], [@R27]\] and investigations were also separated by cancer type \[[@R26], [@R28]\]. As a result, a total of 15 case-control studies with 19796 cases and 49681 controls were included in the final meta-analysis. Of these, sample sizes ranged from 200 to 6512 for cases, and from 400 to 41451 for controls. The genotype distributions of the *MDM4* rs4245739 A \> C polymorphism were in accordance with Hardy-Weinberg equilibrium (HWE) in the controls in all 15 studies. Studies were performed on various types of cancer. Four studies focused on breast cancer \[[@R21], [@R22], [@R26]\], three on lung cancer \[[@R26], [@R27]\], two on esophageal squamous cell carcinoma \[[@R23]\], and one each on non-Hodgkin lymphoma \[[@R24]\], gastric cancer \[[@R25]\], colon cancer \[[@R26]\], prostate cancer \[[@R26]\], ovarian cancer \[[@R28]\] and endometrial cancer \[[@R28]\]. Seven studies were conducted among Caucasians \[[@R21], [@R26], [@R28]\], and eight among Asians \[[@R22]--[@R25], [@R27]\]. All 15 studies were considered high quality; one was scored as 10, eleven as 12 and three as 13.

![Flow diagram of included studies for the association between *MDM4* rs4245739 A \> C polymorphism and overall cancer risk](oncotarget-07-71718-g001){#F1}

###### Characteristics of studies included in the current meta-analysis

  Surname         Year   Cancer type   Country        Ethnicity   Control source   Genotype method   Case   Control   MAF   HWE    Score                                         
  --------------- ------ ------------- -------------- ----------- ---------------- ----------------- ------ --------- ----- ------ ------- ------- ------ ------- ------ ------- ----
  Garcia-Closas   2013   Breast        Multi-center   Caucasian   Mixed            Illumina array    3318   2637      557   6512   22825   15798   2828   41451   0.26   0.183   12
  Liu             2013   Breast        China          Asian       PB               PCR-RFLP          733    67        0     800    686     111     3      800     0.07   0.505   13
  Liu             2013   Breast        China          Asian       PB               PCR-RFLP          278    22        0     300    501     96      3      600     0.09   0.483   12
  Zhou            2013   ESCC          China          Asian       PB               PCR-RFLP          501    37        2     540    478     70      2      550     0.07   0.740   13
  Zhou            2013   ESCC          China          Asian       PB               PCR-RFLP          529    56        3     588    510     88      2      600     0.08   0.379   13
  Fan             2014   NHL           China          Asian       PB               PCR-RFLP          187    13        0     200    346     53      1      400     0.07   0.487   12
  Feng            2014   Gastric       China          Asian       HB               PCR-RFLP          208    209       51    468    210     219     64     493     0.35   0.561   10
  Gansmo          2015   Breast        Norway         Caucasian   PB               LightSNiP assay   966    643       108   1717   1021    703     146    1870    0.27   0.106   12
  Gansmo          2015   Colon         Norway         Caucasian   PB               LightSNiP assay   823    600       108   1531   2042    1439    266    3747    0.26   0.566   12
  Gansmo          2015   Lung          Norway         Caucasian   PB               LightSNiP assay   715    515       101   1331   2042    1439    266    3747    0.26   0.566   12
  Gansmo          2015   Prostate      Norway         Caucasian   PB               LightSNiP assay   1412   927       161   2500   1021    736     120    1877    0.26   0.410   12
  Gao             2015   Lung          China          Asian       PB               PCR-RFLP          297    22        1     320    548     90      2      640     0.07   0.399   12
  Gao             2015   Lung          China          Asian       PB               PCR-RFLP          183    17        0     200    321     77      2      400     0.10   0.248   12
  Gansmo          2016   Ovarian       Norway         Caucasian   HB               LightSNiP assay   716    564       105   1385   1021    703     146    1870    0.27   0.106   12
  Gansmo          2016   Endometrial   Norway         Caucasian   HB               LightSNiP assay   757    541       106   1404   1021    703     146    1870    0.27   0.106   12

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium, ESCC, esophageal squamous cell carcinoma; NHL, non-Hodgkin lymphoma; PB, population based; HB, hospital based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

Meta-analysis results {#s2_2}
---------------------

The overall analysis results are shown in Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}. We found the presence of significant heterogeneity under all genetic models (*P* ^het^\< 0.10); thus, we chose the random-effects model because it can generate wider confidence intervals (CIs). We found that the *MDM4* rs4245739C carriers had a significantly decreased overall cancer risk under the heterozygous \[AC vs. AA: odds ratio (OR) = 0.82, 95% CI = 0.73--0.93\], dominant (AC + CC vs. AA: OR = 0.82, 95% CI = 0.72--0.93), and allele contrast models (C vs. A: OR = 0.84, 95% CI = 0.76--0.94). In the subgroup analysis by ethnicity, similar results were found among Asians (AC vs. AA: OR = 0.55, 95% CI = 0.43--0.70; AC + CC vs. AA: OR = 0.54, 95% CI = 0.43--0.69; and C vs. A: OR = 0.56, 95% CI = 0.44--0.72), but not among Caucasians. When analyses were stratified by the source of controls, significant association with decreased cancer risk was found among population-based studies (AC vs. AA: OR = 0.70, 95% CI = 0.58--0.83; AC/CC vs. AA: OR = 0.70, 95% CI = 0.59--0.83; and C vs. A: OR = 0.73, 95% CI = 0.63--0.85). In the stratified analysis by quality score, significant associations were found among studies with scores ≥12 (AC vs. AA: OR = 0.81, 95% CI = 0.71--0.93; AC + CC vs. AA: OR = 0.81, 95% CI = 0.71--0.92; and C vs. A: OR = 0.84, 95% CI = 0.75--0.93).

![Forest plot for the association between the *MDM4* rs4245739 A \> C polymorphism and cancer risk under the dominant model\
The horizontal lines represent the ORs and 95% CIs of single studies. The diamond represents the pooled OR and 95% CI.](oncotarget-07-71718-g002){#F2}

###### Meta-analysis of the association between *MDM4* rs4245739 A \> C polymorphism and cancer risk

  Variables           No. of studies   Sample size   Homozygous              Heterozygous   Recessive   Dominant                Allele                                                                                                                                
  ------------------- ---------------- ------------- ----------------------- -------------- ----------- ----------------------- ---------- ------ ----------------------- ------- ------ ----------------------- ---------- ------ ----------------------- ---------- ------
  All ^a^             15               19796/49681   1.01 (0.87--1.17)       0.005          54.9        **0.82 (0.73--0.93)**   \< 0.001   85.7   1.00 (0.89--1.14)       0.041   42.6   **0.82 (0.72--0.93)**   \< 0.001   87.4   **0.84 (0.76--0.94)**   \< 0.001   87.9
  Cancer type                                                                                                                                                                                                                                                         
  Breast              4                9329/44721    0.94 (0.55--1.61)       \< 0.001       83.3        0.78 (0.57--1.06)       \< 0.001   92.1   0.95 (0.59--1.51)       0.002   79.3   0.76 (0.55--1.05)       \< 0.001   93.7   0.77 (0.57--1.03)       \< 0.001   94.3
  Lung                3                1851/4787     1.08 (0.84--1.37)       0.762          0.0         0.58 (0.29--1.19)       \< 0.001   90.0   1.07 (0.84--1.35)       0.814   0.0    0.59 (0.29--1.20)       \< 0.001   90.5   0.61 (0.31--1.19)       \< 0.001   90.0
  ESCC                2                1128/1150     1.20 (0.32--4.50)       0.759          0.0         **0.57 (0.43--0.74)**   0.484      0.0    1.27 (0.34--4.79)       0.763   0.0    **0.58 (0.45--0.76)**   0.464      0.0    **0.62 (0.48--0.79)**   0.438      0.0
  Others              6                7488/4640     0.98 (0.87--1.10)       0.953          0.0         1.00 (0.89--1.11)       0.036      58.1   0.97 (0.86--1.09)       0.970   0.0    0.99 (0.89--1.10)       0.041      56.9   0.99 (0.92--1.06)       0.080      49.2
  Ethnicity                                                                                                                                                                                                                                                           
  Caucasians          7                16380/45198   1.03 (0.88--1.22)       \< 0.001       75.3        1.04 (0.97--1.12)       0.012      63.1   1.02 (0.89--1.18)       0.005   67.8   1.04 (0.95--1.13)       \< 0.001   75.1   1.03 (0.95--1.11)       \< 0.001   80.4
  Asians              8                3416/4483     0.78 (0.54--1.14)       0.908          0.0         **0.55 (0.43--0.70)**   0.007      64.0   0.81 (0.56--1.16)       0.918   0.0    **0.54 (0.43--0.69)**   0.007      64.1   **0.56 (0.44--0.72)**   0.001      71.2
  Source of control                                                                                                                                                                                                                                                   
  PB                  11               10027/7737    0.96 (0.85--1.08)       0.763          0.763       **0.70 (0.58--0.83)**   \< 0.001   83.4   0.96 (0.85--1.09)       0.807   0.0    **0.70 (0.59--0.83)**   \< 0.001   84.0   **0.73 (0.63--0.85)**   \< 0.001   84.3
  HB                  3                3257/2363     0.97 (0.81--1.15)       0.623          0.623       1.07 (0.97--1.18)       0.461      0.0    0.94 (0.79--1.11)       0.757   0.0    1.05 (0.96--1.16)       0.387      0.0    1.02 (0.95--1.10)       0.371      0.0
  Mixed               1                6512/41451    **1.36 (1.23--1.49)**   /              /           **1.15 (1.09--1.21)**   /          /      **1.28 (1.16--1.41)**   /       /      **1.18 (1.12--1.24)**   /          /      **1.16 (1.11--1.21)**   /          /
  Quality score                                                                                                                                                                                                                                                       
  ≥ 12                14               19596/49281   1.03 (0.88--1.19)       0.009          53.9        **0.81 (0.71--0.93)**   \< 0.001   86.6   1.02 (0.90--1.16)       0.055   41.0   0.81 (0.71--0.92)       \< 0.001   88.2   **0.84 (0.75--0.93)**   \< 0.001   88.5
  \< 12               1                200/400       0.81 (0.53--1.22)       /              /           0.96 (0.74--1.26)       /          /      0.82 (0.55--1.21)       /       /      0.93 (0.72--1.20)       /          /      0.92 (0.76--1.11)       /          /

Het, heterogeneity; ESCC, esophageal squamous cell carcinoma; HB, hospital based; PB, population based.

The *MDM4* mRNA expression by genotypes {#s2_3}
---------------------------------------

In the genotype-based mRNA expression analysis (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}) using public datasets, we found the rs4245739C allele carriers had trends toward decreased mRNA expression level among Caucasians, Asians, Africans, and all subjects. The decrease in the *MDM4* mRNA expression reached a statistical significance among the Caucasians (AC vs. AA: *P* = 0.002; CC vs. AA: *P* = 0.004, and AC + CC vs. AA: *P* = 0.0002), but not among other populations.

###### *MDM4* mRNA expression by the genotypes of rs4245739 A \> C, using data from the HapMap[^a^](#tfn_001){ref-type="table-fn"}

  Population   genotypes   No.   Mean ± SD     *P*[^b^](#tfn_002){ref-type="table-fn"}   *P*~trend~[^c^](#tfn_003){ref-type="table-fn"}
  ------------ ----------- ----- ------------- ----------------------------------------- ------------------------------------------------
  CEU          AA          52    7.28 ± 0.31                                             0.001
               AC          29    7.06 ± 0.27   0.002                                     
               CC          9     6.96 ± 0.20   0.004                                     
               Dominant    38    7.03 ± 0.26   0.0002                                    
  YRI          AA          59    6.75 ± 0.23                                             0.724
               AC          25    6.72 ± 0.22   0.578                                     
               CC          6     6.68 ± 0.11   0.271                                     
               Dominant    31    6.71 ± 0.20   0.459                                     
  Asian        AA          80    6.86 ± 0.31                                             0.530
               AC          10    6.79 ± 0.23   0.530                                     
               CC          0     /             /                                         
               Dominant    10    6.79 ± 0.23   0.530                                     
  All          AA          191   6.94 ± 0.36                                             0.377
               AC          64    6.88 ± 0.29   0.271                                     
               CC          15    6.85 ± 0.22   0.165                                     
               Dominant    79    6.88 ± 0.28   0.135                                     

CEU, 90 Utah residents with ancestry from northern and western Europe; YRI, 90 Yoruba in Ibadan, Nigeria.

Genotype data and mRNA expression levels for *MDM4* by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals.

Two-sided Student\'s *t* test within the stratum.

*P* values for the trend test of *MDM4* mRNA expression among 3 genotypes for each SNP from a general linear model.

![mRNA expression level of the *MDM4* gene in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines\
(**A**) mRNA expression in 90 cell lines from unrelated CEU (Utah residents with ancestry from northern and western Europe) individuals. (**B**) mRNA expression in 90 cell lines of unrelated YRI (Yoruba in Ibadan, Nigeria) individuals. (**C**) mRNA expression in 90 cell lines of unrelated Asian individuals. (**D**) mRNA expression in 270 cell lines of all individuals.](oncotarget-07-71718-g003){#F3}

Sensitivity analysis and publication bias {#s2_4}
-----------------------------------------

We conducted sensitivity analysis to assess the influence of each individual study on the pooled ORs and 95% CIs by omitting one study each time. No individual study could alter the pooled ORs significantly, which demonstrated that the studies were relatively statistically robust. Additionally, we found that no single study could alter the publication bias in an obvious manner (data not shown).

DISCUSSION {#s3}
==========

In the present meta-analysis comprising 69477 subjects from 15 studies, we completed the first comprehensive evaluation of the association between *MDM4* gene rs4245739 A \> C polymorphism and overall cancer risk. The pooled results indicate that the *MDM4* rs4245739 A \> C polymorphism was significantly associated with decreased overall cancer risk, which was consistent with the results of our genotype-based mRNA expression analysis.

SNPs are the most common type of genetic variations. The majority of SNPs are silent or have limited influence on the function and expression of genes. Only a small fraction of SNPs have been reported to be potentially functional and associated with cancer susceptibility \[[@R29]--[@R32]\], in accordance with the theory of the driver and passenger somatic mutations in human cancer genome \[[@R33]\]. The influence of genetic variations, particularly SNPs, on an individual\'s cancer susceptibility under similar environmental exposures, has been widely investigated and has become a hot research topic worldwide \[[@R34]\]. The association between SNPs and cancer risk may be strongly cancer-specific \[[@R35]\]. Numerous previous studies have investigated the association between *MDM4* gene polymorphisms and cancer susceptibility \[[@R21]--[@R28]\].

The *MDM4* gene (also known as *HDMX* or *MDMX*) is located at chromosome 1q32, a region that is frequently found to be amplified in cancer \[[@R36]\]. This gene contains 11 exons and encodes a protein of 490 amino acids \[[@R37]\], in which at least 2709 SNPs have been identified (<http://www.ncbi.nlm.nih.gov/projects/SNP>). Among these SNPs, a potentially functional polymorphism (rs4245739 A \> C) has received a great deal of recent attention. The rs4245739 A \> C polymorphism was first identified in 40 German patients with familial breast cancer through sequencing the whole coding and flanking untranslated regions of *MDM4* gene \[[@R38]\]. This polymorphism, located in the 3′ UTR of *MDM4* gene, generates a miR-191 target binding site. As a result, miR-191 selectively binds to mRNA harboring the *MDM4* rs4245739C allele to decrease the expression of *MDM4* gene at both mRNA and protein levels, but not mRNA with *MDM4* rs4245739A allele (wild-type). The decreased MDM4 expression caused by miR-191 binding might increase the activity of p53 and consequentially modify an *MDM4* rs4245739A allele carriers\' susceptibility to ovarian cancer and retinoblastoma \[[@R39], [@R40]\]. Additionally, the *MDM4* rs4245739 AC genotype may be associated with increased overall survival in non-small cell lung cancer, when compared to the AA genotype \[[@R41]\]. Despite the biological plausibility, studies investigating the association between this polymorphism and cancer risk have yielded inconclusive results \[[@R21]--[@R28]\]. For instance, some studies found that the rs4245739 A \> C polymorphism was significantly associated with decreased cancer risk \[[@R22]--[@R24], [@R27]\]; in contrast, Garcia-Closas et al. \[[@R21]\]. reported that this polymorphism was associated with increased breast cancer risk. Moreover, others found that this polymorphism may have weak or no effect on cancer risk \[[@R25], [@R26], [@R28]\]. It is widely recognized that different cancer types have unique characteristics and involve differing signal pathways. Even among the same cancer type, cancers from different patients display significant heterogeneity. The possible reasons for discrepancies regarding cancer susceptibility may be ascribed to tumor specificity, differences in ethnicity, and variations in sample sizes included in each investigation. When we combined all available investigations, we found that the rs4245739C allele carriers had decreased cancer risk, especially among Asians. Moreover, we also found that the rs4245739C allele was associated with decreased mRNA expression of *MDM4* by genotype-based mRNA expression analysis, which could provide further biological evidence of the possible mechanism of this polymorphism.

Although this is the first meta-analysis investigating the association between *MDM4* gene rs4245739 A \> C polymorphism and overall cancer risk, some limitations should be discussed. First, although all of the eligible studies were pooled together, the total number of studies and the sample sizes for most types of cancer were still relatively small. As a result, statistical power might be limited while evaluating the association of interest, especially in the subgroup analysis. For instance, there was only one study available for several types of cancer including non-Hodgkin lymphoma, gastric cancer, colon cancer, and prostate cancer. No pooled study could be performed for these cancers. Second, there was heterogeneity among the included studies, which might stem from the inconsistent results derived from different cancers and ethnicities. Third, nearly all of the studies included in this meta-analysis were conducted among Asians and Caucasians. In light of genetic and geographical differences, more investigations from different areas and ethnicities are required to verify our findings. Fourth, the lack of original data limited the further evaluation of potential gene-gene and gene-environment interactions that may modulate cancer risk. Fifth, we may have missed some publications, especially studies without genotype data and those with negative results that were not published. For example, the genotype data for the control subjects were not available in the investigation carried out by Wynendaele et al. \[[@R39]\]. As a result, this study was not included in the current meta-analysis. Finally, publication bias may exist since only published studies were included in our meta-analysis. So, the conclusions drawn from the current study should be interpreted with caution.

In conclusion, our meta-analysis revealed that *MDM4* gene rs4245739 A \> C polymorphism was associated with a reduction in overall cancer susceptibility. Due to the limitations of the current meta-analysis, future studies with larger sample size and different ethnicities and cancer types are needed to confirm these findings.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We conducted a comprehensive literature search for all relevant publications concerning the association between *MDM4* rs4245739 A \> C polymorphism and cancer risk from MEDLINE, EMBASE, and CBM database (prior to 5 September, 2016). The following search terms were used: "*MDM4* or *HDMX* or *MDMX* or *MRP1* or rs4245739", "cancer or carcinoma or tumor or neoplasm", and "polymorphism or variant or variation". We also searched for additional relevant studies from the references of retrieved publications.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Studies meeting the following inclusion criteria were included: (1) evaluated the association between *MDM4* rs4245739 A \> C polymorphism and cancer risk; (2) case-control study or cohort study; (3) genotype distributions were available for both cases and controls; (4) published in English or Chinese.

Exclusion criteria included: (1) not case-control study design; (2) did not evaluate the association between *MDM4* rs4245739 A \> C polymorphism and cancer risk; (3) studies with overlapping participants; (4) conference abstracts, review articles, comments, meta-analyses, or editorial articles. In the case of duplicate or overlapping studies, only the most complete one was included.

Data extraction {#s4_3}
---------------

Two authors (Chaoyi Xu and Jinhong Zhu) independently extracted the following information from each investigation: the first author\'s surname, publication year, country, ethnicity, control source, genotyping method, as well as number of case and control with AA, AC and CC genotypes. All disagreements were resolved through discussion between these two investigators until a consensus was reached.

Genotype-based mRNA expression analysis {#s4_4}
---------------------------------------

We performed genotype-based mRNA expression analysis as we described previously \[[@R3], [@R42]--[@R45]\]. Genotypes data of *MDM4* rs4245739 A \> C polymorphism for 270 individuals with three ethnicities were obtained from HapMap ([http://www.hapmap.org](http://www.hapmap.org/)). The *MDM4* gene mRNA expression data for the same 270 individuals were downloaded from SNPexp (<http://app3.titan.uio.no/biotools/tool.php?app=snpexp>).

Statistical analysis {#s4_5}
--------------------

The strength of the association between *MDM4* rs4245739 A \> C polymorphism and overall cancer risk were assessed using crude OR and 95% CI under the homozygous (CC vs. AA), heterozygous (AC vs. AA), recessive (CC vs. AC + AA), dominant (AC + CC vs. AA), and allele contrast models (C vs. A). Goodness-of-fit χ^2^ test was adopted to test deviation from HWE for the genotypes of control subjects. Heterogeneity was assessed using χ^2^-based *Q* test, and was considered as significant when *P* \< 0.10. We also qualified the heterogeneity using *I*^2^ statistics, a value with a range from 0% to 100%. A higher *I*^2^ value indicates a greater degree of heterogeneity \[[@R46]\]. When significant heterogeneity was found, random-effects model \[[@R47]\] would be adopted; otherwise, fixed-effects model (the Mantel-Haenszel method) \[[@R48]\] would be used. The quality of each investigation was evaluated by quality assessment criteria ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}) as we described previously \[[@R43]\]. Subgroup analysis was conducted by cancer type (investigations with only one study would be merged into the "others" group), ethnicity, source of control and quality score of investigations. Sensitivity analysis was conducted to evaluate the stability of the results. The pooled ORs and 95% CIs were estimated by excluding one study at a time to evaluate the influence of single investigation. The potential publication bias was estimated using Begg\'s funnel plot \[[@R49]\] and Egger\'s linear regression test \[[@R50]\]. In terms of genotype-based mRNA expression, two-sided Student\'s *t* test was used for the comparison of two groups, and one-way ANOVA was adopted for comparison among three different genotypes. The statistical analysis was performed with STATA software (version 11.0; Stata Corporation, College Station, TX). All the statistics were two-sided, with *P* \< 0.05 indicating statistical significance.
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